ResearcherShanghai Medical College of Fudan UniversityNo recent work listed
Qiwen Chen
Matched on ORCID iD 0000-0003-3141-1817; OpenAlex author ID A5052521628. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 24
2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 2 papers
Papers 4
- Overexpression of BUB1B, CCNA2, CDC20, and CDK1 in tumor tissues predicts poor survival in pancreatic ductal adenocarcinoma. Last author DOI 10.1042/bsr20182306↗
- HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients. Co-author DOI 10.2147/ott.s185424↗
- Prognostic values of common clinical parameters in advanced pancreatic ductal adenocarcinoma: a large multicenter cohort study of ten years. Last author PMID 29641971↗
- Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter coh… Co-author DOI 10.18632/oncotarget.13000↗
Closest collaborators
The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Shu Dong · 3 shared papers, 2016–2019 · strength 0.24
- Paper Overexpression of BUB1B, CCNA2, CDC20, and CDK1 in tumor tissues predicts poor survival in pancreatic ductal adenocarci… DOI 10.1042/bsr20182306↗
- Paper Prognostic values of common clinical parameters in advanced pancreatic ductal adenocarcinoma: a large multicenter cohor… PMID 29641971↗
- Paper Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? … DOI 10.18632/oncotarget.13000↗
- Chenyue Zhang · 3 shared papers, 2016–2019 · strength 0.21
- Paper HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patien… DOI 10.2147/ott.s185424↗
- Paper Prognostic values of common clinical parameters in advanced pancreatic ductal adenocarcinoma: a large multicenter cohor… PMID 29641971↗
- Paper Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? … DOI 10.18632/oncotarget.13000↗
- Zhiqiang Meng · 3 shared papers, 2016–2019 · strength 0.21
- Paper HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patien… DOI 10.2147/ott.s185424↗
- Paper Prognostic values of common clinical parameters in advanced pancreatic ductal adenocarcinoma: a large multicenter cohor… PMID 29641971↗
- Paper Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? … DOI 10.18632/oncotarget.13000↗
- Zhouyu Ning · 2 shared papers, 2016–2019 · strength 0.15
- Paper HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patien… DOI 10.2147/ott.s185424↗
- Paper Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? … DOI 10.18632/oncotarget.13000↗
- Fei Huang · 1 shared paper, 2019 · strength 0.14
- Libin Song · 1 shared paper, 2019 · strength 0.11
- Jing Xie · 1 shared paper, 2019 · strength 0.11
- Yehua Shen · 2 shared papers, 2016–2018 · strength 0.11
- Lei Wang · 2 shared papers, 2016–2018 · strength 0.11
- Yuanbiao Guo · 2 shared papers, 2016–2018 · strength 0.11
- Jinming Yu · 2 shared papers, 2016–2018 · strength 0.11
- Qing-Long Deng · 1 shared paper, 2018 · strength 0.07
- Hao Chen · 1 shared paper, 2018 · strength 0.07
- Zhaoshen Li · 1 shared paper, 2018 · strength 0.07
- Yongqiang Hua · 1 shared paper, 2016 · strength 0.04
- Lanyun Feng · 1 shared paper, 2016 · strength 0.04
- Jing Xie · 1 shared paper, 2016 · strength 0.04
- Luming Liu · 1 shared paper, 2016 · strength 0.04
- Zhao‐Shen Li · 1 shared paper, 2016 · strength 0.04
- Zhen Chen · 1 shared paper, 2016 · strength 0.04
- Hao Chen · 1 shared paper, 2016 · strength 0.04
- Weidong Shi · 1 shared paper, 2016 · strength 0.04
- Xiaoyan Zhu · 1 shared paper, 2016 · strength 0.04
- Lianyu Chen · 1 shared paper, 2016 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.